Get started

Pfelong

Pfizer (PFE) -> It Is Now Or NeverMy name is Philip, I am a German swing-trader with 4+ years of trading experience and I only trade stocks , crypto , options and indices 🖥️ I only focus on the higher timeframes because this allows me to massively capitalize on the major market swings and cycles without getting caught up in the short term noise. This is how you build real long term wealth! In today's anaylsis I want to take a look at the bigger picture on Pfizer. At the moment Pfizer stock is once again retesting major sructure at the psychological $33 level which already acted as pretty strong support in the past. Considering that the next support level below current price is at $27, Pfizer is now trading at a pretty decisive potential turning point and has not yet broken structure towards the downside. - - - - - - - - - - - - - - - - - - - - I know that this is a quite simple trading approach but over the past 4 years I've realized that simplicity and consistency are much more important than any trading strategy. Keep the long term vision🫡
NYSE:PFELong
by basictradingtv
20
PFIZER (PFE) 6M Trading Analisys (TA)6M Chart, PFE , on February 6, 2023, the signals on MACD have been steadily moving NE, after piercing below the histogram on July 2012; On July 2021, reached its ATH (All Time High); The RSI signal bounced over 70 and is now facing SE to test the line of 50, after bouncing up from it on January 2020; The price has been steadily falling since the ATH, from $60 to $43, heading down to test the 100 days MA signal, at this moment there is a probability for the price to bounce up before continuing its way down to test the 100 MA signal, which is the optimistic approach, but remember "In this business if you're good, you're right six times out of ten. You're never going to be right nine times out of ten. I've found that when the market's going down and you buy funds wisely, at some point in the future you will be happy. You won't get there by reading: "Now is the time to buy". Today this ticker has a Volume of 5.297M with a Market Cap of 246B. This Company PAYS DIVIDENDS TO SHAREHOLDERS Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY. Good Luck! Gráfico de 6M, ( PFE ), al 6 de febrero de 2023, las señales en MACD se han estado moviendo constantemente hacia el NE, luego de cruzarse por debajo del histograma en julio de 2012; En julio de 2021, alcanzó su ATH (Mayor Precio Histórico); La señal RSI rebotó sobre 70 y ahora se dirige al SE para probar la señal de 50, luego de rebotar ahi en enero de 2020; El precio ha estado cayendo constantemente desde el ATH, de $60 a $43, bajando para probar la señal de 100 días MA, en este momento existe la probabilidad de que el precio rebote antes de continuar su camino hacia abajo para probar la señal de 100 MA, que es el enfoque optimista, pero recuerda: "En este negocio, si eres bueno, tienes razón seis de cada diez veces. Nunca vas a tener razón nueve de cada diez veces. Descubrí que cuando el mercado está cayendo y compras fondos sabiamente, en algún momento en el futuro serás feliz. No llegarás allí leyendo: "Ahora es el momento de comprar". Hoy este ticker tiene un Volumen de 5.297M con una Capitalización de Mercado de 246B. Esta Empresa PAGA DIVIDENDOS A LOS ACCIONISTAS Pfizer Inc. es una compañía biofarmacéutica global basada en la investigación. Se dedica al descubrimiento, desarrollo, fabricación, comercialización, venta y distribución de productos biofarmacéuticos en todo el mundo. La firma trabaja en mercados desarrollados y emergentes para promover el bienestar, la prevención, los tratamientos y las curas que desafían las enfermedades más temidas. La empresa fue fundada por Charles Pfizer Sr. y Charles Erhart en 1849 y tiene su sede en Nueva York, NY. ¡Buena suerte! “I believe in analysis and not forecasting.” / "Creo en el análisis y no en el pronóstico". REMEMBER : I am not a financial adviser nor is any content in this article presented as financial advice. The information provided in this blog post and any other posts that I make, and any accompanying material is for informational purposes only. It should not be considered financial or investment advice of any kind. One should consult with a financial or investment professional to determine what may be best for your individual needs. RECUERDE : No soy un asesor financiero y el contenido de este artículo no se presenta como asesoramiento financiero. La información provista en esta publicación de blog y cualquier otra publicación que haga y cualquier material que la acompaña es solo para fines informativos. No debe considerarse asesoramiento financiero o de inversión de ningún tipo. Se debe consultar con un profesional financiero o de inversiones para determinar qué es lo mejor para sus necesidades individuales.
NYSE:PFELong
by rodulfox
PFE: Sell Zone is 58-60Pfizer's W-4 bottomed right in our "Buy Zone" and has bounced 10% since. I expect Pfizer to continue to climb up to the $58-60 level over the coming 2 weeks or so. After that, Pfizer will pull back for it's larger degree W-2, which should bring price back to about the $50 level. We will have more clarity on pullback targets once W-5 tops, most likely in our "selling zone". The point is, this is not an idea time to start a position. I will be selling covered calls against my shares of Pfizer when we reach the selling zone, and will be looking to add shares for about $50 sometime in Late May/Early June.
NYSE:PFELong
by TomDaSpankEngine
PFE Long IdeaPFE Weekly Chart : - Broke Downtrend trend line. - Meet 10 EMA on the weekly = important resistance : we are seeing rejection of the 51-50 levels. - Holding 48$ level is crucial for PFE to stay in it current uptrend. Above 51 PFE will likely go for the gap fill to reach around 52.70. - With current market condition it is probable to have some kind of pullback next week : key point here is we need to see lower volume pullback with smaller candle than green candle. Optimal scenario is that we see a bounce back immediately after a pullback. That will signal relative strength and constant buying of the stock.
NYSE:PFELong
by phongthienphihong
Long PfizerWhile the overall markets have been beaten down due to inflation, rate hikes combined with high asset prices, and the war in Ukraine, certain assets have been certainly rising like fuel and commodities. I'm almost looking at Pfizer as a commodity at this point since they have become so integral in the fight against COVID. Who knows what the future holds for Pfizer or the possibility of a 4th vaccination round. Right now all I know is that the price is bouncing nicely off the the 200-day SMA for the first time in a while. I'm also inclined to believe that the markets are due for a lift back up soon, so this could coincide with that idea, or even lead the charge. Opinion only, not financial advice.
NYSE:PFELong
by tyler_sim
1
PFE Pfizer to All Time HighIf you haven`t bought at my first call, when PFE was $40: Than you should know that Pfizer’s vaccine with BioNTech SE is on track to be the best-selling drug product on a yearly basis and received backing from a European regulatory panel on Thursday to expand its use into children as young as five. Still low PE Ratio (TTM) 15.42 Decent Forward Dividend & Yield 1.56 (2.89%) The stock jumped also on the promise of its antiviral pill! For me is a Buy even at this level!
NYSE:PFELong
by TopgOptions
1
PFE is bullish with Aspen Trading Support & Resistance LevelsPFE has bounced up from support @ 41.5 using Aspen Trading Support & Resistance Levels. Next target is 49.5 and a move above this level can lead to further upside. More tailwinds, it is above 50 & 200 moving averages and PFE typically displays seasonal strength this time of year. Please like, share and follow if you agree with the analysis. Note - Aspen Trading S/R levels are invite only. They can be accessed through my profile information. Disclaimer: This analysis is for information purpose only and does not constitute any investment advice.
FX:PFELong
by tradingswift
Pfizer | Fundamental Analysis | Must Read ⚡️Pfizer has grown an authority at being first. The pharmaceutical behemoth was the pioneer to introduce a coronavirus vaccine a year ago. Since then, it has had several other successes: bringing the COVID-19 booster to market, getting approval for its vaccine for adolescents, and most recently getting approval for a vaccine for children. This has been followed by a lot of revenue. Moreover, the company recently raised its revenue forecast for coronavirus vaccines this year to $36 billion. Pfizer also raised its total revenue forecast to at least $81 billion as demand for the company's other drugs grows as well. At the same time, the company's stock is up about 18% this year. So now the big question is: Is it too late to buy Pfizer stock? First, let's look at Pfizer's performance now and what may lie ahead. Last week, Pfizer reported a 134 percent increase in third-quarter revenue to $24.1 billion. That includes sales of the coronavirus vaccine. It's impossible to say exactly how much sales of this drug will grow after the pandemic, but it looks like sales of the vaccine could remain at the "best-seller" level for a long time to come. Experts say the virus will persist into the future, so we need protection - and that means regular vaccinations. As recent studies have shown, immunity declines a few months after the initial vaccination. Let's take a look at what Pfizer itself says about future vaccine revenues. During its earnings report, the company said that some projections of vaccine revenue for 2022 look "very high," and offered more moderate projections. Pfizer projected vaccine revenue for 2022 at $29 billion, based on the delivery of 1.7 billion doses. That's still a pretty impressive level. And that figure could be higher. Pfizer can produce 4 billion doses, and the company is still negotiating with governments. Meanwhile, two elements are helping Pfizer continue to gain market share for coronavirus vaccines: the booster and the use of the vaccine in children and adolescents. The company is just getting started in these areas, so they clearly can help boost orders as countries plan the number of doses needed for next year and beyond. The competitor's Moderna vaccine is not yet available for teens and children in the U.S. This means that Pfizer has an opportunity to dominate these age groups. At the same time, Pfizer is moving closer to conquering another COVID-19 market: the treatment market. The company's investigational coronavirus pill is currently in late-stage clinical trials. The company says trial data could be available as early as this quarter. The potential pill could be a game-changer because it could be prescribed immediately after a person is diagnosed with COVID-19 and could be taken at home. Competing company Merck, however, maybe first on the market with a potential pill treatment. It has already requested approval for its drug. But given the need for such a drug, both companies could generate billions of dollars in revenue in this area. Analysts talk a lot about coronavirus. But the reality is that Pfizer has many other sources of revenue today - and potential in the future. This means that Pfizer can continue to thrive even if sales of the COVID-19 vaccine stall or decline. The drivers of today's revenue are seven other drugs. Two of them, the blood-thinning drug Eliquis and the cardiovascular drugs Vyndaqel/Vyndamax, posted double-digit revenue growth in the third quarter. Pfizer has 94 programs in development. Of these, 29 are in phase 3 trials. This is cause for optimism about the company's ability to make up for possible declines in sales of its older drugs. As mentioned earlier, Pfizer stock is up this year, but the stock is only trading at 10 times earnings guidance. This is a bargain, given Pfizer's near- and long-term growth prospects. Pfizer's growing return on invested capital and free cash flow are two more reasons to be optimistic about the stock. Pfizer is also a good bet for income-seeking investors. The company just paid its 331st consecutive quarterly dividend. So, is it too late to buy Pfizer? Not if you're a long-term investor. Pfizer stock hasn't soared as fast as stocks of biotech companies involved in the fight against the coronavirus. And they're unlikely to do so in the future. But Pfizer has plenty of fuel for incremental earnings growth in the future - and that should lead to sustained, long-term stock price gains.
NYSE:PFELong
by FOREXN1
7
PFE STRONG AF: All indicators point to continued strong uptrend I REALLY liking PFE rn for long. Here is why ~ Today it not only crossed the VWAP, but it broke the 75th percentile indicating upcoming higher highs. ~ Not only is it riding above the VWAP rn, but there is a nice gap between the price action and SMMA indicating a continued uptrend ~ Price action > 30 EMA > 200 EMA and there is a nice gap between both EMAs. this setup signifies a strong uptrend and an excellent long entry. (especially paired with the fact that the VWAP was crossed) ~ We are maintaining a strong uptrend already on the 50 MA and hourly chart with the 50 MA being a solid support line. I am swinging a PFE call atm (ITM) as PFE is about to be overbought but is not there yet. I believe we may see another test of 50.50 before the pullback. I am hoping we can break it, but if not 50.50 will become a great support zone once we do pass it. I am planning on selling at 50-60 percent profit ( I am at 49 percent rn) and am going to reenter when we retest the VWAP.
NYSE:PFELong
by MathewPiedoux
PFE Uptrend Strong Waiting for pullback to 50 MAPfizer is in a strong uptrend and its hourly keeps coming back to the 50 MA. Each time it has come back to the 50 MA, it has met at a support area. I believe we may see PFE run a bit higher before it returns to the 50 MA as the RSI is undecided (although slightly on a decline). The hourly wicks also do not show any signs of a pullback yet, which supports this idea of a new ATH in the making. I am holding my PFE call until I see some more resistance, but once the tide changes for short term bears I will sell and wait until PFE pulls back to 48.50 (and closes green after touching the 50 MA) before entering calls.
NYSE:PFE
by MathewPiedoux
1
PFE Pfizer short term Price TargetWith the new Covid-19 Delta Variant which is more contagious than the other virus strains the question is if you want to get vaccinated or get COVID-19. PFE Pfizer has a great vaccine, a decent P/E Ratio (TTM) of 20.34, pays Forward Dividend & Yield of 1.56 (3.89%) and it is not at all time high like MRNA for example. Expected sales from vaccine in 2021: $15bn-$30bn My short term price target is 44usd. i`m looking forward to read your opinion about it.
NYSE:PFELong
by TopgOptions
6